Immix Bio hits 2-month high on cancer treatment results in mice

Immix Biopharma

20/05/2022 16:15

** Shares of cancer drug developer Immix Biopharma Inc
 IMMX.O  surge 66% to 2-month-high of $2.70
    ** Set for its best day since it publicly listed in Dec.
2021, if gains hold; among top three pct. gainers and most
active vols across U.S. exchanges
    ** Co says its lead product candidate, IMX-110, showed 75%
survival in mice with connective tissue cancer after one cycle
of treatment, vs. 0% survival with trabectedin, a common cancer
treatment sold under the name Yondelis by Johnson & Johnson's
 JNJ.N  Janssen Pharma  urn:newsml:reuters.com:*:nGNXbjkWzx
    ** About 67 mln shares have traded hands, over 488x stock's
25-DMA
    ** Up to Thursday's close, stock has fallen 67.4% from its
IPO price of $5/shr in Dec. 2021

 (Reporting by Ruhi Soni in Bengaluru)
 ((Ruhi.Soni@thomsonreuters.com
Twitter: https://twitter.com/ruhithere))